Literature DB >> 19424619

Novel expression profiles and invasiveness-related biology function of DKK1 in endometrial carcinoma.

Nuo Yi1, Qin-Ping Liao, Ting Li, Yan Xiong.   

Abstract

DKK1 is a negative regulator in the Wnt signal transduction pathway. It can inhibit the pathway's activation. Previous studies in some malignant tumors revealed the possibility that DKK1 is involved in tumorigenesis inducing abnormalities of the Wnt signal pathway. In this study, we showed that in benign and malignant endometrium, DKK1 exhibited novel expression profiles and invasiveness-related biology function: DKK1 was expressed in both glandular epithelium and matrix of two kinds of endometrium tissues and mostly distributed in the cytoplasm and epicytes of endometrial carcinoma (EC) Ishikawa cell line. DKK1 expression level in EC was significantly lower than that in benign endometrium. The expression correlated well with histology and clinical stage of EC. Exogenous DKK1 suppressed invasiveness of EC cells. Taken together, DKK1 is involved in genesis and early phase of EC by suppressing the invasiveness via the Wnt signal pathway. It shows promise as a biomarker for screening the progression of EC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424619     DOI: 10.3892/or_00000370

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Authors:  Thanh H Dellinger; Kestutis Planutis; Danielle D Jandial; Ramez N Eskander; Micaela E Martinez; Xiaolin Zi; Bradley J Monk; Randall F Holcombe
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

Review 2.  Wnt signalling in implantation, decidualisation and placental differentiation--review.

Authors:  S Sonderegger; J Pollheimer; M Knöfler
Journal:  Placenta       Date:  2010-08-15       Impact factor: 3.481

3.  Group B streptococcus activates transcriptomic pathways related to premature birth in human extraplacental membranes in vitro.

Authors:  Hae-Ryung Park; Sean M Harris; Erica Boldenow; Richard C McEachin; Maureen Sartor; Mark Chames; Rita Loch-Caruso
Journal:  Biol Reprod       Date:  2018-03-01       Impact factor: 4.285

4.  Crosstalk of estrogen receptors and Wnt/β-catenin signaling in endometrial cancer.

Authors:  Mariz Kasoha; Chrisoula Dernektsi; Anita Seibold; Rainer M Bohle; Zoltan Takacs; Iordache Ioan-Iulian; Erich-Franz Solomayer; Ingolf Juhasz-Böss
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-21       Impact factor: 4.553

5.  Prokineticin 1 induces Dickkopf 1 expression and regulates cell proliferation and decidualization in the human endometrium.

Authors:  Linsay J Macdonald; Kurt J Sales; Vivien Grant; Pamela Brown; Henry N Jabbour; Rob D Catalano
Journal:  Mol Hum Reprod       Date:  2011-05-05       Impact factor: 4.025

Review 6.  Targeting Wnt Signaling in Endometrial Cancer.

Authors:  Iram Fatima; Susmita Barman; Rajani Rai; Kristina W W Thiel; Vishal Chandra
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

Review 7.  Participation of WNT and β-Catenin in Physiological and Pathological Endometrial Changes: Association with Angiogenesis.

Authors:  Jolanta Kiewisz; Tomasz Wasniewski; Zbigniew Kmiec
Journal:  Biomed Res Int       Date:  2015-08-20       Impact factor: 3.411

8.  RNA interference-mediated targeting of DKK1 gene expression in Ishikawa endometrial carcinoma cells causes increased tumor cell invasion and migration.

Authors:  Nuo Yi; Qin-Ping Liao; Zhen-Hua Li; Bao-Jiang Xie; Yu-Hong Hu; Wei Yi; Min Liu
Journal:  Oncol Lett       Date:  2013-07-03       Impact factor: 2.967

9.  Involvement of the Wnt signaling pathway and cell apoptosis in the rat hippocampus following cerebral ischemia/reperfusion injury.

Authors:  Bin Liu; Jing Tang; Shiying Li; Yuqin Zhang; Yan Li; Xiaoliu Dong
Journal:  Neural Regen Res       Date:  2013-01-05       Impact factor: 5.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.